The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities
The initial consideration for the transaction is US$ 12 million
One task, one interaction, one pair, experts advocate
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder
Subscribe To Our Newsletter & Stay Updated
